NuVasive Inc

NuVasive — Q2 2018 Earnings Presentation

14 slides from NuVasive's earnings presentation, Jul 31, 2018

  1. Slide 1: Q2 2018 Results Supplemental Presentation to Earnings Press Release

    Q2 2018 Results Supplemental Presentation to Earnings Press Release July 31, 2018 Exhibit 99.2

  2. Slide 2: Forward-Looking Statements

    NuVasive, Inc. (“NuVasive,” “NUVA” or the “Company”) cautions you that statements included in this presentation that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove co

  3. Slide 3: Non-GAAP Financial Measures

    Management uses certain non-GAAP financial measures such as non-GAAP earnings per share, non-GAAP net income, non-GAAP operating expenses and non-GAAP operating profit margin, which exclude amortization of intangible assets, business transition costs, one-time restructuring and related items in conn

  4. Slide 4: Financial Performance

    Q2 2018 Financial Performance GAAP diluted earnings per share increase of 5% to $0.22 and non-GAAP diluted earnings per share of $0.58, up 29% despite flat U.S. market GAAP operating profit margin of 10.1% and non-GAAP operating profit margin of 16.3% Total revenue increased to $281.6 million, up 8.

  5. Slide 5: Revenue Drivers

    Q2 2018 Revenue Drivers U.S. Spinal Hardware Includes all Implants, Fixation and NuVasive Specialized Orthopedics (NSO) $150.8 5.6% Growth in case volume of ~7%, and contributions from new product introductions, partially offset by typical pricing pressure U.S. Surgical Support Includes Biologics, I

  6. Slide 6: P&L Performance Non-GAAP Measures

    Q2 2018 P&L Performance Non-GAAP Measures 2Q 2018 Actuals 2Q 2018 YoY Performance Factors Gross Margin 72.8% 170 bps below prior year of 74.5%; the variance to prior year primarily driven by slower production throughput at the West Carrollton facility and addition of SafePassage Sales, Marketing & A

  7. Slide 7: U.S. Revenue Trends

    U.S. Revenue Trends U.S. Spinal Hardware Growth U.S. Biologics Growth *Normalized for impact of SafePassage and Biotronic acquisitions. Organic NCS Growth* NUVA long-term growth rates above market New product introductions the key enabler Services business scales through growth via new accounts and

  8. Slide 8: West Carrollton Productivity

    West Carrollton Productivity Cost per Unit Savings Improvement (on average) Insourcing Business Case SKUs Insourced Improved Profitability Increased Utilization from Insourcing Procurement Productivity Improved Throughput FY’19 FY’18 Incremental Volume Savings on Unit Cost +130-150 bps Economies of

  9. Slide 9: New Innovations

    Q2 2018 New Innovations* *Some products not commercially released; NuVasive may not make these products available for commercial sale. STRYDE Surgical Automation Platform Versatile Fixation System Limb Lengthening System Anterior Column Realignment through Expandable Technology MAGEC X Early Onset S

  10. Slide 10: An Ecosystem Committed to Delivering Better Surgery

    RIGHT PATIENT Patient Engagement Care Management Patient Selection RIGHT PLAN Pre-Op Plan Intra-Op Assessment Post-Op Confirmation RIGHT PROCEDURE OR Workflow Access Total Fusion Visual Guidance RIGHT SAFETY Radiation Reduction Neurophysiologist Services Integrated IOM RIGHT SMART TOOLS Patient-spec

  11. Slide 11: Introducing PULSE: Surgical Automation Platform

    Integrated Platform Independent Wireless Access Optimized Workflow Advanced Navigation Open Imaging Platform Introducing PULSE® Bringing Surgical Intelligence to Life in the OR Surgical Automation Platform

  12. Slide 12: Updated 2018 Full-Year Guidance

    Updated 2018 Full-Year Guidance* *NuVasive financial performance guidance as of July 31, 2018, inclusive of SafePassage (closed January 2018) **Comparisons to prior year reflect re-casted financial information for 2017 to reflect full retrospective method of adoption of ASC 606. Commencing with the

  13. Slide 13: 2018 Full-Year Financial Performance Guidance

    2018 Full-Year Financial Performance Guidance* Financial Measures FY18 Guidance Performance Drivers Revenue (as reported) $1,095M - $1,105M 6.7% to 7.6% growth Includes SafePassage contribution; ~$3M currency tailwind U.S. Spinal Hardware U.S. Surgical Support International 1) ~2% to ~3% YoY growth

  14. Slide 14: For questions, contact investorrelations@nuvasive.com

    For questions, contact investorrelations@nuvasive.com.

Nuvasive — Q2 2018 Earnings Presentation on 6ix